Welcome to this year’s Clinical Trials Roundup where we’ll reflect on research initiated in 2016, dissecting the data to survey the current trial landscape. In past roundups, our high-level overviews primarily focused on unapproved drug activity within Trialtrove’s six major therapeutic areas (TAs) of autoimmune/inflammation (A/I), cardiovascular (CV), CNS, infectious disease (ID), metabolic/ endocrinology, and oncology. While useful in understanding competitive drug development strategies, this excluded the numerous trials supporting market or label expansion endeavors, as well as the smaller, but not insignificant, TAs of genitourinary and ophthalmology.

To capture the full universe of the competitive trial landscape, this year marks the launch of the next generation of the Clinical Trials Roundup, which will include all Phase I to III clinical research starting within 2016, regardless of the primary drug status. As usual, we’ll begin with metrics by TA, trial phase, and disease, then zoom in on the most active industry sponsors, before wrapping up the roundup with a geographical survey of trial activity. Since this year’s dataset is more inclusive, and has a later snapshot date than years past, minimal comparisons will be made to last year’s analysis.